Heart Failure, Stenosis and Tricuspid

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

FEBRUARY 15, 2024

Food and Drug Administration ( FDA ) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.

Tricuspid

Tricuspid Heart Valves Quality of Life Bicuspid/Mitral

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

APRIL 2, 2024

Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected. and Lynn C.

Tricuspid

Tricuspid Heart Valves Quality of Life Open-Heart Surgery

Eagleâ€™s Eye View: Sacubitril/Valsartan in Decompensated Heart Failure; Discordant Aortic Stenosis and Transcatheter Treatment of Tricuspid Valve Regurgitation

American College of Cardiology

MARCH 27, 2024

In this weekâ€™s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis.

Heart Failure

Heart Failure Stenosis Aortic Tricuspid

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

European Journal of Heart Failure

FEBRUARY 26, 2025

Proposed approach for clinical management and therapeutic optimization in patients with heart failure with reduced ejection fraction and low blood pressure. Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.

Blood Pressure

Blood Pressure Heart Failure Aortic valve TAVR

AISAP’s CARDIO AI-powered Diagnostic Assessment Software Receives FDA Clearance

DAIC

AUGUST 27, 2024

We know that structural heart disease and heart failure are the leading causes of hospitalization and morbidity in the U.S. Standalone performance for significant major valve disease pathology (aortic stenosis and regurgitation and mitral and tricuspid regurgitation) had a 93 percent sensitivity and 93 percent specificity.

Ultrasound

Ultrasound Tricuspid Bicuspid/Mitral Aortic

Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left?sided valvular heart disease in Europe. Insights from the ESC?EORP Valvular Heart Disease II survey

European Journal of Heart Failure

FEBRUARY 19, 2024

Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. ESC-EORP, European Society of Cardiology-EURObservational Research Programme; TV, tricuspid valve.

Tricuspid

Tricuspid Heart Disease Bicuspid/Mitral Heart Valves

Quantitative fluid overload in severe aortic stenosis refines cardiac damage and associates with worse outcomes

European Journal of Heart Failure

OCTOBER 30, 2023

Assessment of fluid overload identifies aortic stenosis (AS) patients at high risk and treatment of fluid overload may potentially improve the post-interventional clinical course. Aims Cardiac decompensation in aortic stenosis (AS) involves extra-valvular cardiac damage and progressive fluid overload (FO).

Stenosis

Stenosis Aortic Aortic valve Outcomes

Evaluation of JVP

All About Cardiovascular System and Disorders

MARCH 20, 2024

And that will be the approximate level of the tricuspid valve, the reference point for measuring right atrial pressure. But while compressing here in a patient with heart failure, it can elicit pain because there could be tender hepatomegaly in patients with heart failure. X descent, X prime descent and Y descent.

Tricuspid

Tricuspid Pericarditis VSD Heart Failure

Coronary microvascular dysfunction in patients undergoing transcatheter aortic valve implantation

Heart BMJ

MARCH 22, 2024

Moreover, we sought to test the correlation between angiography-derived index of microcirculatory resistance (IMR angio ) and invasive IMR in patients with aortic stenosis (AS). The primary endpoint was the composite of cardiovascular death and rehospitalisation for heart failure (HF).

Aortic valve

Aortic valve Aortic Tricuspid Heart Failure

Cardiovascular Research Foundation, CRF, Introduces New York Valves: The Structural Heart Summit

DAIC

APRIL 5, 2024

New York Valves marks the next iteration of this legacy, featuring three days of transformative research and techniques that will redefine the landscape of structural heart interventions. Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aortic stenosis.

Research

Research Heart Disease Best Practices Education

CRG Introduces New York Valves: The Structural Heart Summit

DAIC

APRIL 5, 2024

New York Valves marks the next iteration of this legacy, featuring three days of transformative research and techniques that will redefine the landscape of structural heart interventions. Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aortic stenosis.

Heart Disease

Heart Disease Best Practices Education Tricuspid

Predictors of outcome in patients with moderate mixed aortic valve disease

Heart BMJ

APRIL 25, 2024

Objectives Grading the severity of moderate mixed aortic stenosis and regurgitation (MAVD) is challenging and the disease poorly understood. Methods Moderate MAVD was defined as coexisting moderate aortic stenosis (aortic valve area (AVA) 1.0–1.5 –1.5 cm 2 ) and moderate aortic regurgitation (vena contracta (VC) 0.3–0.6

Aortic valve

Aortic valve Aortic Outcomes Myocardial Infarction

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Right ventricular dysfunction and impaired right ventricular–pulmonary arterial coupling in paradoxical low‐flow, low‐gradient aortic stenosis

European Journal of Heart Failure

DECEMBER 19, 2024

AF, atrial fibrillation; LAVI, left atrial volume index; RA, right atrial; RV, right ventricular; sPAP, systolic pulmonary artery pressure; SVI, stroke volume index; TR, tricuspid regurgitation. Aims Paradoxical low-flow, low-gradient aortic stenosis (pLFLG AS) may represent a diagnostic challenge, and its pathophysiology is complex.

Stenosis

Stenosis Aortic Pulmonary Aortic valve

Cardiovascular Update

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

Eagleâ€™s Eye View: Sacubitril/Valsartan in Decompensated Heart Failure; Discordant Aortic Stenosis and Transcatheter Treatment of Tricuspid Valve Regurgitation

Webinars

Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

AISAP’s CARDIO AI-powered Diagnostic Assessment Software Receives FDA Clearance

Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left?sided valvular heart disease in Europe. Insights from the ESC?EORP Valvular Heart Disease II survey

Quantitative fluid overload in severe aortic stenosis refines cardiac damage and associates with worse outcomes

Evaluation of JVP

Coronary microvascular dysfunction in patients undergoing transcatheter aortic valve implantation

Cardiovascular Research Foundation, CRF, Introduces New York Valves: The Structural Heart Summit

CRG Introduces New York Valves: The Structural Heart Summit

Predictors of outcome in patients with moderate mixed aortic valve disease

Published Research

Published Research

Right ventricular dysfunction and impaired right ventricular–pulmonary arterial coupling in paradoxical low‐flow, low‐gradient aortic stenosis

Stay Connected